Division of General Thoracic Surgery, Mayo Clinic, Rochester, MN, USA.
Eur J Cardiothorac Surg. 2013 May;43(5):911-4. doi: 10.1093/ejcts/ezs520. Epub 2012 Sep 26.
A new revision of the international lung cancer staging system has been recently introduced. The revisions are largely focussed on the T descriptor. We sought to test the validity of this new system on a separate prospectively collected cohort of patients from a recent multicentre trial of early-stage lung cancer.
We reviewed the prospectively collected data from 1012 patients undergoing pulmonary resection for early-stage lung cancer in the ACOSOG Z0030 trial. TNM descriptors and overall staging were assessed using both the sixth and seventh editions of the American Joint Committee on Cancer and the Union Internationale Contre le Cancer (AJCC/UICC) lung cancer staging system. Survival results were analysed according to both staging allocations.
Using the proposed criteria, the number of patients by stage in the sixth and seventh edition allocations, respectively, were as follows: IA (432, 431); IB (402, 303); IIA (39, 167); IIB (94, 70); IIIA (26, 40); IIIB (19,0); there were no stage IV patients by either version. Overall, 180 (18%) patients had a change in the stage group from the sixth to seventh edition versions with 76 (8%) being downstaged and 104 (10%) being upstaged. In the sixth edition staging system based on pathological stages, median survivals in years were as follows: IA, NA; IB, 7.7; IIA, 4.0; IIB, 3.6; IIIA, 2.6 and IIIB, 2.4. Five-year survivals were: IA, 76.4%; IB, 62.0%; IIA, 47.8%; IIB, 40.4%; IIIA, 31.3% and IIIB, 44.4%. In the new system, median survivals in years were as follows: IA, NA; IB, 8.2; IIA, 4.4; IIB, 3.6 and IIIA, 1.8. Five-year survivals were: IA, 76.9%; IB, 65.0%; IIA, 48.5%; IIB, 42.9% and IIIA, 30.6%. Survival analysis and Kaplan-Meier survival curves showed more monotonic progression, distinction and homogeneity within groups in the seventh edition.
This study provides an external validation of the recently revised lung cancer staging system using a large multicentre database. The seventh edition of the AJCC/UICC lung cancer staging system appears to be an improvement over the preceding system.
最近引入了国际肺癌分期系统的新版本修订。修订主要集中在 T 描述符上。我们试图在最近的一项早期肺癌多中心试验的另一个前瞻性收集队列中测试这个新系统的有效性。
我们回顾了 ACOSOG Z0030 试验中 1012 例接受肺切除术治疗的早期肺癌患者的前瞻性收集数据。使用第六和第七版美国癌症联合委员会/国际抗癌联盟(AJCC/UICC)肺癌分期系统评估 TNM 描述符和总体分期。根据两种分期分配方法分析生存结果。
使用提出的标准,第六版和第七版分配的各期患者数量如下:IA(432,431);IB(402,303);IIA(39,167);IIB(94,70);IIIA(26,40);IIIB(19,0);两种版本均无 IV 期患者。总体而言,180 例(18%)患者的分期组从第六版到第七版发生变化,76 例(8%)降期,104 例(10%)升期。在基于病理分期的第六版分期系统中,中位生存年限如下:IA,NA;IB,7.7;IIA,4.0;IIB,3.6;IIIA,2.6 和 IIIB,2.4。5 年生存率分别为:IA,76.4%;IB,62.0%;IIA,47.8%;IIB,40.4%;IIIA,31.3%和 IIIB,44.4%。在新系统中,中位生存年限如下:IA,NA;IB,8.2;IIA,4.4;IIB,3.6 和 IIIA,1.8。5 年生存率分别为:IA,76.9%;IB,65.0%;IIA,48.5%;IIB,42.9%和 IIIA,30.6%。生存分析和 Kaplan-Meier 生存曲线显示,第七版在组内具有更单调的进展、区分和同质性。
本研究使用大型多中心数据库为最近修订的肺癌分期系统提供了外部验证。第七版 AJCC/UICC 肺癌分期系统似乎优于前一版。